Diagnosis and
Management of Hepatocellular
Carcinoma: 2009 Update
Target Audience
This activity has
been designed to meet the
educational needs of hepatologists,
gastroenterologists, physician
assistants, and nurse practitioners
involved in the management of
chronic liver disease.
Goal Statement
To provide important
clinical data on the management of
hepatocellular carcinoma (HCC)
Educational
Objectives
Upon completion of
this activity, participants should
be better able to:
Credit Designation
• Review the epidemiology and
etiology of HCC
1.0 AMA PRA Category
1 Credit(s)™
• Describe the latest treatment
advances
• Discuss the latest treatment
algorithms for the management of HCC
Please see page 1 of
the monograph for full accreditation
statement.
Jointly sponsored by
Purdue University School of
Pharmacy and the Chronic
Liver Disease Foundation.
This educational material
was supported by grants from
Bayer Healthcare LLC and
Onyx Pharmaceuticals.
RPL36 as a prognostic marker in hepatocellular carcinoma Song MJ, Jung CK, Park CH, Hur W, Choi JE, Bae SH, Choi JY, Choi SW, Han NI, Yoon SK. Pathol Int. 2011 Nov;61(11):638-44. doi: 10.1111/j.1440-1827.2011.02716.x. Epub 2011 Sep 23.
MELD Exceptions and Rates of Waiting List Outcomes Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, Schnitzler MA, Gheorghian A, Salvalaggio PR, Segev DL. Am J Transplant. 2011 Sep 15. doi: 10.1111/j.1600-6143.2011.03735.x. [Epub ahead of print]
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Aliment Pharmacol Ther. 2011 Aug 24. doi: 10.1111/j.1365-2036.2011.04823.x. [Epub ahead of print]
Hepatitis C virus-related hepatocellular carcinoma and liver cirrhosis Pecic V, Stankovic-Djordjevic D, Nestorovic M, Radojkovic M, Marjanovic H, Ilic B, Milojkovic M. J BUON. 2011 Apr-Jun;16(2):277-81. Source Clinic for General Surgery, Clinical Center Nis, Nis, Serbia. acrepus@yahoo.com
Comparison of staging systems of hepatocellular carcinoma Sirivatanauksorn Y, Tovikkai C. HPB Surg. 2011;2011:818217. Epub 2011 Jun 27. Sources HPB and Transplantation Unit, Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Survival after (90) Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S; on behalf of European Network on Radioembolization with yttrium-90 resin microspheres (ENRY). Hepatology. 2011 May 26. doi: 10.1002/hep.24451. [Epub ahead of print]
Racial differences in hepatitis C treatment eligibility Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; on behalf of the IDEAL Study Team. Hepatology. 2011 Apr 12. doi: 10.1002/hep.24358. [Epub ahead of print]
Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; The Japan NASH Study Group, The Ministry of Health, Labour and Welfare of Japan. Clin Gastroenterol Hepatol. 2011 Feb 11. [Epub ahead of print]
Liver Cancer Working Group report Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i19-27.
Sorafenib in advanced hepatocellular carcinoma Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. N Engl J Med. 2008 Jul 24;359(4):378-90
Design and endpoints of clinical tria ls in hepatocellular carcinoma Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. J Natl Cancer Inst. 2008 May 21;100(10):698-711. Epub 2008 May 13
Hepatocellular carcinoma in patients with cryptogenic cirrhosis
Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group. Clinical Gastroenterol Hepatol. 2009;7:580-5.
Sorafenib in Advanced Hepatocellular Carcinoma
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, de Oliveira A, Santoro A, Raoul J, Former A, Schwartz M, Porta C, Zeuzem, Bolondi L, Greten T, Galle P, Seitz J, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, and Bruix J for the SHARP Investigators Study Group. N Engl J Med 2008;359:378-90.